Oct. 22 - Naturex continued to enjoy sustained growth over the third quarter of 2007, posting revenues of EUR 18.3 million, up 21.7%.
Revenues for the first nine months of the year stood at EUR 60.1 million, up 21.0%. Proforma growth stood at 13.4% at constant USD rates and 7.7% at current USD rates.
Accordingly, Naturex's activity over the first nine months of the year is in with its development plan as the Group pursues its aggressive commercial strategy against a buoyant market backdrop.
Naturex will report its 2007 full-year revenues on January 28, 2008.
|
In EUR millions |
2006 |
2007 |
Change 2007/2006 |
Change 2007/proforma 2006* at constant USD |
|
First quarter |
18.3 |
21.2 |
+15.6% |
+12.1% |
|
Second quarter |
16.3 |
20.6 |
+26.4% |
+15.8% |
|
Third quarter |
15.1 |
18.3 |
+21.7% |
+12.2% |
|
9 months |
49.7 |
60.1 |
+21.0% |
+13.4% |
*With the integration of Hammer Pharma from January 1, 2006 and HP Botanicals from April 1, 2006